Kemwell Biopharma has expanded its analytical capabilities in India to service an FTE contract for a large, multinational pharma company. The new analytical lab is equipped with 10 HPLC’s, one UPLC and nine dissolution apparatus and other analytical instruments. Kemwell will also employ 15 scientists dedicated to this project.
 
Ninad Deshpanday, president of R&D at Kemwell, said, “This project and lab expansion further reflects Kemwell’s commitment to its customers. Kemwell has invested in a dedicated facility to meet the needs of this very important customer. The scope of the project includes method transfer, stability sample analyses and analytical method validation for various projects for the customer. We are actively looking to invest in and grow our development business.”
 
Kemwell’s R&D division employs more than 100 scientists and provides services from formulation development, analytical development and validation to clinical trial manufacturing.